Analysis of the Ability of Different Allografts to Act as Carrier Grafts for Local Drug Delivery

ORCID
0000-0001-8050-437X
Affiliation
Julius Wolff Institut und BIH-Center für Regenerative Therapien und Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, 13353 Berlin, Germany;(N.B.);(A.S.);(M.S.K.);(B.W.)
Bormann, Nicole;
Affiliation
Julius Wolff Institut und BIH-Center für Regenerative Therapien und Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, 13353 Berlin, Germany;(N.B.);(A.S.);(M.S.K.);(B.W.)
Schmock, Aysha;
Affiliation
German Institute for Cell and Tissue Replacement (DIZG, gemeinnützige GmbH), 12555 Berlin, Germany;(A.H.);(V.E.);(J.C.B.)
Hanke, Anja;
Affiliation
German Institute for Cell and Tissue Replacement (DIZG, gemeinnützige GmbH), 12555 Berlin, Germany;(A.H.);(V.E.);(J.C.B.)
Eras, Volker;
ORCID
0000-0003-1536-4651
Affiliation
German Institute for Cell and Tissue Replacement (DIZG, gemeinnützige GmbH), 12555 Berlin, Germany;(A.H.);(V.E.);(J.C.B.)
Ahmed, Norus;
Affiliation
Julius Wolff Institut und BIH-Center für Regenerative Therapien und Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, 13353 Berlin, Germany;(N.B.);(A.S.);(M.S.K.);(B.W.)
Kissner, Maya S.;
GND
120936208
ORCID
0000-0002-8365-1188
Affiliation
Julius Wolff Institut und BIH-Center für Regenerative Therapien und Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, 13353 Berlin, Germany;(N.B.);(A.S.);(M.S.K.);(B.W.)
Wildemann, Britt;
ORCID
0000-0002-4395-6411
Affiliation
German Institute for Cell and Tissue Replacement (DIZG, gemeinnützige GmbH), 12555 Berlin, Germany;(A.H.);(V.E.);(J.C.B.)
Brune, Jan C.

Bone defects and infections pose significant challenges for treatment, requiring a comprehensive approach for prevention and treatment. Thus, this study sought to evaluate the efficacy of various bone allografts in the absorption and release of antibiotics. A specially designed high-absorbency, high-surface-area carrier graft composed of human demineralized cortical fibers and granulated cancellous bone (fibrous graft) was compared to different human bone allograft types. The groups tested here were three fibrous grafts with rehydration rates of 2.7, 4, and 8 mL/g (F(2.7), F(4), and F(8)); demineralized bone matrix (DBM); cortical granules; mineralized cancellous bone; and demineralized cancellous bone. The absorption capacity of the bone grafts was assessed after rehydration, the duration of absorption varied from 5 to 30 min, and the elution kinetics of gentamicin were determined over 21 days. Furthermore, antimicrobial activity was assessed using a zone of inhibition (ZOI) test with S. aureus . The fibrous grafts exhibited the greatest tissue matrix absorption capacity, while the mineralized cancellous bone revealed the lowest matrix-bound absorption capacity. For F(2.7) and F(4), a greater elution of gentamicin was observed from 4 h and continuously over the first 3 days when compared to the other grafts. Release kinetics were only marginally affected by the varied incubation times. The enhanced absorption capacity of the fibrous grafts resulted in a prolonged antibiotic release and activity. Therefore, fibrous grafts can serve as suitable carrier grafts, as they are able to retain fluids such as antibiotics at their intended destinations, are easy to handle, and allow for a prolonged antibiotic release. Application of these fibrous grafts can enable surgeons to provide longer courses of antibiotic administration for septic orthopedic indications, thus minimizing infections.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © 2023 by the authors.

Use and reproduction: